Table 2.
CEA for newborn screening for CAH: year 2005, discount rate 3%
| Range | ICER (USD/life-year saved) |
|
|---|---|---|
| Traditional CEA | ||
| Base-case analysis | 128,200 | |
| Best-case analysis | 15,700 | |
| Worst-case analysis | 706,600 | |
| One-way sensitivity analysis of base-case analysis | ||
| (1) Cost per screening infant without follow-up | USD 2.3 | 80,900 |
| USD 6.0 | 175,600 | |
| (2) Cost of follow-up and confirmatory test per screen positive | USD 130 | 117,300 |
| USD 637 | 182,000 | |
| (3) Screen false-positive rate | 0.1% | 105,800 |
| 1.0% | 156,300 | |
| (4) Incidence of CAH | 1 in 25,000 | 182,300 |
| 1 in 12,000 | 84,700 | |
| (5) SW mortality without screening | 2.0% | 269,300 |
| 9.0% | 59,800 | |
| (6) Reduction in SW mortality with screening | 74% | 138,600 |
| 86% | 119,300 | |
CEA, cost-effectiveness analysis; CAH, congenital adrenal hyperplasia; SW, salt wasting; ICER, incremental cost-effectiveness ratio.